Highest response rates to TKIs in patients with EGFR-TK mutatio

来源: 26484915 于 2014-11-11 11:56:18 [] [博客] [旧帖] [给我悄悄话] 阅读数 : (784 bytes)
本帖于 2014-11-11 12:01:02 时间, 由普通用户 26484915 编辑

EGFR is expressed on the cell surface of a substantial percentage of NSCLCs. Initial studies with the EGFR tyrosine kinase inhibitors (TKIs) gefitinib (Iressa) and erlotinib (Tarceva) demonstrated biologic and clinical activity in only a relatively limited subset of lung cancers.[4]

Further investigation demonstrated that the highest response rates to these TKIs were seen in patients with somatic mutations within the EGFR-TK domain, particularly exon 19 deletion, exon 21 L858R, and exon 18 G719X.[5]

By contrast, the exon 20 T790M mutation is associated with acquired resistance to TKI therapy.[6]

http://emedicine.medscape.com/article/1689988-overview

所有跟帖： 

• 能否明言是否有效？引文看起来太难。 -litianxin- ♀ 给 litianxin 发送悄悄话 (0 bytes) () 11/11/2014 postreply 11:59:06

• Iressa/Tarceva 对有 EGFR exon 21 突变者有效率高。 -26484915- ♂ 给 26484915 发送悄悄话 26484915 的博客首页 (6 bytes) () 11/11/2014 postreply 12:00:41

• 国内建议特罗凯？有效吗？ -litianxin- ♀ 给 litianxin 发送悄悄话 (0 bytes) () 11/11/2014 postreply 12:02:55

• 易瑞沙和特罗凯. 特罗凯= Tarceva -26484915- ♂ 给 26484915 发送悄悄话 26484915 的博客首页 (0 bytes) () 11/11/2014 postreply 12:04:44

• 2种药都是口服药，没有必要住院。 -26484915- ♂ 给 26484915 发送悄悄话 26484915 的博客首页 (0 bytes) () 11/11/2014 postreply 12:40:00

• 用周边血检测的基因突变，而不是活检，是否准确？ -litianxin- ♀ 给 litianxin 发送悄悄话 (0 bytes) () 11/11/2014 postreply 12:09:11

• 血检说有突变那就是有。血检说没有不一定没有。 -26484915- ♂ 给 26484915 发送悄悄话 26484915 的博客首页 (0 bytes) () 11/11/2014 postreply 12:11:50

• 多谢 -litianxin- ♀ 给 litianxin 发送悄悄话 (0 bytes) () 11/11/2014 postreply 12:12:58

请您先登陆，再发跟帖！